MS PLoS dataset

Excel file extract from MS Access database describing clinical studies indentified in the review, and our assessment of their risk of bia

Short-listed interventions ranked by overall drug scores.

<p>* Amiloride added to the shortlist at committee review based on awareness of relevant but unpublished data. Scores for amiloride were then calculated following publication of this data.</p><p>Short-listed interventions ranked by overall drug scores.</p

Scoring method for evaluation of study quality.

<p>Following systematic review, study quality was evaluated according to previously published criteria (CAMARADES, Delphi, and GRADE—see text). A maximum of 24 points were available by the sum of these individual score</p><p>Scoring method for evaluation of study quality.</p

Eligibility criteria for publications included in systematic review.

<p>Data on efficacy was defined as (the) “reporting of change in clinical status (relapse frequency, disability progression, behavioural symptoms) or changes in biomarkers of clinical status (magnetic resonance imaging (MRI), blood, cerebral spinal fluid (CSF))”.</p

Selection process for publications & interventions.

<p>Selection process for publications & interventions.</p

Effect of shortlisted interventions on neurobehavioural and pathological outcomes in EAE.

<p>Symbols represent the point estimates of efficacy for interventions. Symbol sizes represent the log₁₀ of the number of animals contributing to that comparison. The vertical line represents the line of no effect.</p

Candidate interventions excluded during short-listing.

<p>MOA = mechanism of action</p><p>Candidate interventions excluded during short-listing.</p